Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 1, 2013, Pages 81-90

  Hu, C C ^a,b   Lin, C L ^a,b   Kuo, Y L ^a   Chien, C H ^a   Chen, S W ^a   Yen, C L ^a   Lin, C Y ^a,b   Chien, R N ^a,b,c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c Chang Gung Memorial Hospital ^*  (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELDERLY CARE; FEMALE; FEVER; FOLLOW UP; GENOTYPING TECHNIQUE; GERIATRIC ASSESSMENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MOUTH ULCER; MYALGIA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; THROMBOCYTOPENIA; VIRUS DETECTION;

EID: 84870601065     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12112     Document Type: Article

References (42)

1. Alter MJ,. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-41.
2. Tsukuma H, Hiyama T, Tanaka S, et al,. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.
3. Fassio E,. Hepatitis C and hepatocellular carcinoma. Ann Hepatol 2010; 9 (Suppl.): 119-22.
4. Lauer GM, Walker BD,. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
5. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP,. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
6. Chen DS, Kuo GC, Sung JL, et al,. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990; 162: 817-22.
7. Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC,. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007; 106: 148-55.
8. Thabut D, Le Calvez S, Thibault V, et al,. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006; 101: 1260-7.
9. Marcellin P, Asselah T, Boyer N,. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36 (Suppl. 1): S47-56.
10. Colombo M, de Franchis R, Del Ninno E, et al,. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-80.
11. Chuang WL, Yu ML, Dai CY, Chang WY,. Treatment of chronic hepatitis C in southern Taiwan. Intervirology 2006; 49: 99-106.
12. McHutchison JG, Gordon SC, Schiff ER, et al,. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
13. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
14. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
15. Iwasaki Y, Ikeda H, Araki Y, et al,. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43: 54-63.
16. Hiramatsu N, Oze T, Tsuda N, et al,. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? Hepatol Res 2006; 35: 185-9.
17. Nudo CG, Wong P, Hilzenrat N, Deschenes M,. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol 2006; 20: 589-92.
18. Antonucci G, Longo MA, Angeletti C, et al,. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol 2007; 102: 1383-91.
19. Imai Y, Kasahara A, Tanaka H, et al,. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. J Gastroenterol 2004; 39: 1069-77.
20. Arase Y, Ikeda K, Suzuki F, et al,. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007; 50: 16-23.
21. Huang CF, Yang JF, Dai CY, et al,. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010; 201: 751-9.
22. McHutchison JG, Manns M, Patel K, et al,. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
23. Lin DY, Sheen IS, Chiu CT, Lin SM, Kuo YC, Liaw YF,. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. J Clin Ultrasound 1993; 21: 303-8.
24. Honda T, Katano Y, Shimizu J, et al,. Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver Int 2010; 30: 527-37.
25. Kainuma M, Furusyo N, Kajiwara E, et al,. Pegylated interferon alpha-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 2010; 16: 4400-9.
26. Official statistical reports of population's life span. Department of Health, Executive Yuan, ROC. Available at: http://www.doh.gov.tw/CHT2006/DM/DM2- 2.aspx?now-fod-list-no=10177&class-no=440&level-no=2. Accessed October 10, 2011.
27. Yu ML, Dai CY, Huang JF, et al,. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-93.
28. Liu CH, Liu CJ, Lin CL, et al,. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47: 1260-9.
29. Everson GT,. Management of cirrhosis due to chronic hepatitis C. J Hepatol 2005; 42 (Suppl.): S65-74.
30. Hadziyannis SJ, Sette H Jr, Morgan TR, et al,. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
31. Liu CJ, Chuang WL, Lee CM, et al,. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009; 136: 496-504 e3.
32. Giannini EG, Basso M, Savarino V, Picciotto A,. Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. Dig Dis Sci 2010; 55: 3193-9.
33. Yu ML, Chuang WL,. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009; 24: 336-45.
34. Ascione A, De Luca M, Tartaglione MT, et al,. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138: 116-22.
35. Sezaki H, Suzuki F, Kawamura Y, et al,. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2009; 54: 1317-24.
36. Okanoue T, Itoh Y, Hashimoto H, et al,. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol 2009; 44: 952-63.
37. Yoshida H, Arakawa Y, Sata M, et al,. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123: 483-91.
38. Ikeda K, Saitoh S, Arase Y, et al,. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-30.
39. Imazeki F, Yokosuka O, Fukai K, Saisho H,. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003; 38: 493-502.
40. Backus LI, Boothroyd DB, Phillips BR, Mole LA,. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46: 37-47.
41. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
42. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.